Comparative Pharmacology
Head-to-head clinical analysis: HALOETTE versus LUNELLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOETTE versus LUNELLE.
HALOETTE vs LUNELLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity.
Lunelle is a combination contraceptive injection containing medroxyprogesterone acetate and estradiol cypionate. It suppresses gonadotropin secretion, inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.
One 13.9 mg subcutaneous etonogestrel implant inserted into the inner side of the non-dominant upper arm for contraception; effective for 3 years.
150 mg intramuscular injection on day 5 of menstrual cycle, then every 90 days thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3–1.7 hours (mean 1.5 hours). The short half-life supports continuous intravenous infusion for sustained sedation in critical care.
Terminal elimination half-life of 20-30 hours in healthy adults; prolonged to 40-60 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinically, steady state reached in 4-5 days.
Renal excretion of metabolites accounts for approximately 85–90% of elimination; biliary/fecal excretion accounts for 10–15%.
Primarily renal (~70% as unchanged drug and inactive metabolites), with ~20% biliary/fecal elimination. Minimal dose recovered in feces as parent compound.
Category C
Category C
Contraceptive
Contraceptive